Highlights Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			5-day change	1st Jan Change
23.2 ^USD	+6.52%		-3.25%	-0.64%

11/06	Wolfe Research Initiates Coverage on Akero Therapeutics With Outperform Rating, $40 Price Target	MT
11/06	Akero Therapeutics, Inc. Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Akero Therapeutics, Inc. Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH	11/06	CI
Akero Therapeutics Announces Two Presentations Featuring Its Lead Product Candidate Efruxifermin At the European Association for the Study of the Liver Congress 2024	08/06	CI
Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027	10/05	MT
Akero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology	08/03	CI
Health Care Down on Growth Doubts -- Health Care Roundup	05/03	DJ
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell as Traders Hope for Clues to Timing of Rate Cuts	04/03	MT
Akero's lead drug helps improve scarring in fatty liver disease patients	04/03	RE
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study	04/03	CI
Akero Therapeutics' Q4 Loss Widens; Cash Expected to Fund Operations Into 2026	29/02	MT
Akero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Akero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program	18/12	CI
Akero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins	10/23/10	CI
Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH	10/23/10	CI
Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology	04/23/04	CI
Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023	28/23/28	CI
Akero Therapeutics' Shares Gain Nearly 5% After Reporting Narrower Q2 Loss; Efruxifermin in Phase 2 Clinical Development	11/23/11	MT
Akero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Highlights

Filters